MedPage Today - "Meta-Analysis Gives Xience Stent Safety Advantage"

 – September 15, 2011 /Press Release/  –– 

The second-generation everolimus-eluting stent may carry a lower risk of stent thrombosis compared with other drug-eluting stents, a meta-analysis showed. In a pooled analysis of 13 randomized trials, the rate of definite or probable stent thrombosis was 0.7 percent with the everolimus-eluting stent and 1.5 percent with the other mostly first-generation drug-eluting stents, according to George Dangas, MD, PhD, of The Mount Sinai Medical Center in New York City, and colleagues. Learn more.